CME Information
Target Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.
Goal
Given the dramatic advances in medical management of advanced disease in the last two years, this discussion of the NCCN Kidney Cancer Guidelines will focus on the selection and sequencing of drugs and biologics, the role of cytokine therapy in unresectable or recurrent renal cell carcinoma, and the role of targeted therapy options in unresectable and recurrent renal cell carcinoma. Implications of these findings and guideline updates also will be discussed.
Learning Objectives
Following this activity, participants should be able to:
- Describe the response rate and side effect profiles associated with cytokine therapy;
- List the mechanism of action and indications for use of newer targeted agents for unresectable and recurrent kidney cancer;
- Discuss the sequencing of systemic therapy following progression after first-line therapy.
Credits Available
Physicians - maximum of 0.75
AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.8 ANCC contact hours
All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
Accreditation Statements
Learning Objectives
Following this activity, participants should be able to:
- Describe the response rate and side effect profiles associated with cytokine therapy;
- List the mechanism of action and indications for use of newer targeted agents for unresectable and recurrent kidney cancer;
- Discuss the sequencing of systemic therapy following progression after first-line therapy.
Author Disclosures
Gary R. Hudes, MD
Disclosure: Dr. Hudes has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has served as a speaker for Bayer HealthCare Pharmaceuticals and Pfizer Inc. He has also served on advisory boards for Genentech, Inc. and Pfizer Inc.
Dr. Hudes has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Timothy M. Kuzel, MD
Disclosure: Dr. Kuzel has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has served as a speaker for Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals and Pfizer Inc. and as a principal investigator for Genentech, Inc. He has also served on advisory boards for Pfizer Inc. and Wyeth.
Dr. Kuzel has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Robert J. Motzer, MD
Disclosure: Dr. Motzer has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has served as an investigator for Genentech, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Wyeth. He has also served on the speakers bureau for Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals.
Dr. Motzer has indicated that his presentation will include discussion of investigational or unlabeled uses of RAD001 (everolimus).
For Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians.
NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity:
webcasts@nccn.org. For technical assistance, contact
CME@webmd.net.
For Nurses
This activity is approved for 0.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.
Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
More Activities from NCCN
Release Date: March 5, 2008; Valid for credit through March 5, 2009
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or printed out.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score of 80% or higher. In addition, you must complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
Hardware/Software Requirements
Medscape requires version 4.x browsers or higher from Microsoft or Netscape. Certain educational activities may require additional software to view multimedia, presentation or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.
